Mineralys Therapeutics, Inc. financial data

Symbol
MLYS on Nasdaq
Location
150 N. Radnor Chester Road, Suite F200, Radnor, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.43K % -13.4%
Return On Equity -70.4 % -65.3%
Return On Assets -65.5 % -63.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.3M shares +33.3%
Common Stock, Shares, Outstanding 65.7M shares +32.2%
Entity Public Float 400M USD +66.6%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 65.5M shares +32.6%
Weighted Average Number of Shares Outstanding, Diluted 65.5M shares +32.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 175M USD +50.3%
General and Administrative Expense 28.4M USD +54.9%
Operating Income (Loss) -203M USD -51%
Nonoperating Income (Expense) 12.3M USD -17.2%
Net Income (Loss) Attributable to Parent -191M USD -59.4%
Earnings Per Share, Basic -3 USD/shares -32.6%
Earnings Per Share, Diluted -3 USD/shares -32.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 102M USD +50%
Assets, Current 335M USD +5.43%
Property, Plant and Equipment, Net 22K USD -47.6%
Other Assets, Noncurrent 433K USD -3.56%
Assets 336M USD +5.41%
Accounts Payable, Current 3.16M USD +85.4%
Accrued Liabilities, Current 19M USD -28.8%
Liabilities, Current 22.2M USD -21.9%
Retained Earnings (Accumulated Deficit) -388M USD -96.7%
Stockholders' Equity Attributable to Parent 314M USD +8.09%
Liabilities and Equity 336M USD +5.41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.5M USD -138%
Net Cash Provided by (Used in) Financing Activities 189M USD +62.9%
Net Cash Provided by (Used in) Investing Activities -92.9M USD -66%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 65.7M shares +32.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.9M USD +23.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 102M USD +50%
Deferred Tax Assets, Valuation Allowance 79.9M USD +154%
Deferred Tax Assets, Gross 79.9M USD +154%
Deferred Tax Assets, Operating Loss Carryforwards 15.6M USD +97.5%
Unrecognized Tax Benefits 4.51M USD +319%
Additional Paid in Capital 702M USD +44%
Depreciation, Depletion and Amortization 15K USD +87.5%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 14.5M USD +78.7%